Financials in USD. Standardized financial statements.
A compact view of how Avalo Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $59,000 | $441,000 | $1.92M | $18.05M | $5.40M | $6.70M | $6.75M | $18.33M | $27.81M | $1.15M |
| Revenue Growth? | -86.6% | -77.1% | -89.3% | +234.4% | -19.4% | -0.8% | -63.2% | -34.1% | +2312.2% | 0.0% |
| Cost of Revenue? | $0 | -$366,000 | $1.28M | $3.43M | $1.49M | $300,000 | -$566,523 | $7.48M | $635,648 | $8.24M |
| Gross Profit? | $59,000 | $807,000 | $640,000 | $14.62M | $3.91M | $6.40M | $7.32M | $10.85M | $27.18M | -$7.09M |
| Gross Margin? | +100.0% | +183.0% | +33.3% | +81.0% | +72.4% | +95.5% | +108.4% | +59.2% | +97.7% | -614.6% |
| Operating Expenses? | $72.98M | $69.32M | $27.99M | $52.06M | $86.04M | $6.40M | $23.45M | $29.52M | $13.29M | $17.23M |
| Operating Income? | -$72.92M | -$68.51M | -$27.35M | -$37.44M | -$82.13M | $0 | -$16.14M | -$39.31M | $13.89M | -$16.08M |
| EBITDA? | -$72.58M | -$68.34M | -$23.29M | -$37.27M | -$80.48M | -$45.45M | -$13.51M | -$13.07M | $14.35M | -$16.05M |
| Income Before Tax | -$78.09M | -$35.02M | -$31.53M | -$41.63M | -$84.55M | -$67.18M | -$15.99M | -$40.09M | $13.84M | -$16.47M |
| Income Tax Expense | $165,000 | $114,000 | $14,000 | $28,000 | -$196,000 | -$2.79M | $280,316 | -$33,910 | $1.97M | $364,144 |
| Net Income? | -$78.26M | -$35.13M | -$31.54M | -$41.66M | -$84.38M | -$63.50M | -$16.07M | -$40.05M | $11.87M | -$16.47M |
| EPS? | $-5.84 | $-4.32 | $-113.58 | $-1062.65 | $-2330.66 | $-2523.77 | $-819.74 | $-3317.28 | $1856.88 | $-21.93 |
| Diluted EPS? | $-5.84 | $-3.26 | $-113.58 | $-1062.65 | $-2330.66 | $-2523.77 | $-819.74 | $-3317.28 | $1822.74 | $-21.93 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality